Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

32P Brachytherapy for the treatment of ALHE: a case report with 8 years follow-up

Jinshan ZHANG
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1387;
Jinshan ZHANG
1Department of Nuclear Medicine and Radiation Oncology the Third Affiliated Hospital of Guangzhou Medical Guangzhou China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1387

Objectives: Angiolymphoid hyperplasia with eosinophilia(ALHE) is a distinctive benign vascular disease. The challenge of ALHE is the treatment. Various modalities of the therapies have been used to treat ALHE without the consistent results. We present a case of ALHE on the right auricle in a 56-year-old Chinese woman who underwent brachytherapy by 32P simple-drug membranes with a promising results of near 8 years follow-up. This case indicating that 32P Brachytherapymay be a novel method for the treatment of ALHE with a favorable long-term outcome.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
32P Brachytherapy for the treatment of ALHE: a case report with 8 years follow-up
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
32P Brachytherapy for the treatment of ALHE: a case report with 8 years follow-up
Jinshan ZHANG
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1387;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
32P Brachytherapy for the treatment of ALHE: a case report with 8 years follow-up
Jinshan ZHANG
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1387;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Other Solid Tumors Posters

  • Assessment of SPECT-CT fusion images and semi-quantitative evaluation using SUV parameter of I-123 IMP SPECT in patients with ocular choroidal melanoma.
  • The role of 18F-FDG PET/CT in the evaluation of pericardial effusion
  • Predicting Efficacy of Radium-223 Dichrolide (223RaCl2) therapy in Bone-metastatic Castration-resistant Prostate Cancer Using F-18 Sodium Fluoride (18F-NaF) PET/CT.
Show more Other Solid Tumors Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire